Abu Dhabi’s state-backed health-care investment company M42 has taken a stake in biotech startup Juvenescence, a UK-based firm focused on developing drugs to expand human lifespans.
M42, which was established through the combination of the health-care assets of two of Abu Dhabi’s investment firms, is investing an undisclosed amount into Juvenescence at a valuation of over $550 million, according to a statement.
The two firms will also form a strategic partnership focused on using artificial intelligence to develop therapeutics to treat life-threatening diseases and extend healthy life spans.
“With Juvenescence, we are unlocking the potential of AI to transform ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.